Lumexa Imaging (NASDAQ:LMRI) Releases FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.710-0.770 for the period, compared to the consensus EPS estimate of 0.620. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Lumexa Imaging Price Performance

Shares of NASDAQ:LMRI traded up $0.07 during trading on Wednesday, hitting $11.73. 735,578 shares of the company were exchanged, compared to its average volume of 790,443. Lumexa Imaging has a 1-year low of $6.45 and a 1-year high of $19.45. The company has a market capitalization of $1.13 billion and a P/E ratio of -19.88. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.43. The business’s 50 day moving average is $10.62 and its 200-day moving average is $10.94.

Lumexa Imaging (NASDAQ:LMRI) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter. The firm had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Equities analysts forecast that Lumexa Imaging will post 0.27 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LMRI has been the topic of a number of recent research reports. Barclays cut their price target on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 20th. Weiss Ratings raised Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research note on Thursday, June 25th. Finally, Wall Street Zen lowered shares of Lumexa Imaging from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lumexa Imaging currently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Insiders Place Their Bets

In related news, Director Brett Brodnax bought 35,000 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was acquired at an average cost of $7.25 per share, with a total value of $253,750.00. Following the transaction, the director directly owned 62,027 shares in the company, valued at approximately $449,695.75. This trade represents a 129.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is owned by insiders.

Institutional Trading of Lumexa Imaging

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC acquired a new position in shares of Lumexa Imaging in the 4th quarter worth approximately $1,548,000. Goldman Sachs Group Inc. acquired a new position in Lumexa Imaging in the fourth quarter valued at $18,870,000. TD Asset Management Inc bought a new stake in shares of Lumexa Imaging during the 4th quarter valued at about $1,264,000. JPMorgan Chase & Co. bought a new position in shares of Lumexa Imaging during the 4th quarter worth approximately $15,954,000. Finally, Federated Hermes Inc. acquired a new position in shares of Lumexa Imaging during the 4th quarter valued at $8,325,000.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).